TITLE

Toxicity assessment

PUB. DATE
September 2004
SOURCE
WHO Technical Report Series;2004, Issue 927, p44
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article explains the importance of toxicity assessment in the evolving field of vaccine development. The scientific judgment in nonclinical safety studies should be employed in data interpretation from the studies concerning the risk-benefit ratio, animal testing and dosing. Before vaccines are used on clinical trials in humans, the general framework provided in the section of the World Health Organization guidelines on nonclinical evaluation of vaccines will be the minimum requirement for the safety assessment.
ACCESSION #
19839142

 

Related Articles

  • Basic toxicity assessment.  // WHO Technical Report Series;2004, Issue 927, p45 

    The article discusses the World Health Organization guidelines in evaluating the potential toxic effects of a vaccine. The guidelines specified the parameters relevant in designing animal toxicology studies. It clarified that the potential effects of the product should be evaluated with regard...

  • PROPOSAL TO DISCONTINUE THE TEST FOR UNDUE TOXICITY (CHAPTER 3.7) IN THE INTERNATIONAL PHARMACOPOEIA (September 2019).  // WHO Drug Information;2019, Vol. 33 Issue 4, p769 

    The article discusses a proposal to omit the test for undue toxicity in the World Health Organization's (WHO) "The International Pharmacopoeia." Topics discussed include the scientific rationale for performing the innocuity test on vaccines and other biologicals, test for undue toxicity of...

  • Additional toxicity assessments.  // WHO Technical Report Series;2004, Issue 927, p48 

    The article focuses on the sections of the World Health Organization guidelines on nonclinical evaluation of vaccines concerning the additional toxicity assessment. When the findings of the evaluation of immune response from both clinical and nonclinical studies showed immunological aspects of...

  • Neglected diseases fund touted. Butler, Declan // Nature;5/20/2010, Vol. 465 Issue 7296, p277 

    The article focuses on the problem regarding drugs and vaccines for neglected diseases such as tuberculosis and dengue fever that did not reached clinical development. It says that one of its hindrances is the amount of running clinical trials for commercial companies. However, a consortium of...

  • General.  // WHO Technical Report Series;2004, Issue 926, p1 

    Focuses on the activity of the World Health Organization (WHO) units responsible for biological standardization in meeting the targets set for 2002–2003. Involvement of WHO in the standardization activities at an early stage in the development of new vaccines; Awareness of WHO on the need...

  • International recommendations, guidelines and other matters related to the manufacture and quality control of biologicals.  // WHO Technical Report Series;2004, Issue 926, p8 

    Focuses on the draft recommendations and guidelines of the World Health Organization Expert Committee for the production and quality control of biologicals. Need for stringent requirements for a vaccine intended for emergency use; Risk factors associated with the manufacture of inactivated...

  • Non-clinical Assessment of New Drug Products. Hamrell, Michael R. // Drug Development;2010, Vol. 5, p30 

    Multidisciplinary product development programmes use pre-clinical or non-clinical safety evaluation studies to provide sufficient understanding of a product's pharmacology and toxicological potential prior to the initiation of studies in humans. In addition to providing insights into a product's...

  • Integration of Computational Analysis as a Sentinel Tool in Toxicological Assessments. Pearl, Greg M.; Lvingston-Carr, Sondra; Durham, Stephen K. // Current Topics in Medicinal Chemistry;Sep2001, Vol. 1 Issue 4, p247 

    Computational toxicity modeling can have significant impact in the drug discovery process, especially when utilized as a sentinel filter for common drug safety liabilities, such as mutagenicity, carcinogenicity and teratogenicity. This review will focus on the strengths and limitations of the...

  • Assessing the Potential Toxicity of New Pharmaceuticals. Johnson, Dale E.; Wolfgang, Grushenka H.I. // Current Topics in Medicinal Chemistry;Sep2001, Vol. 1 Issue 4, p233 

    Optimizing chemical structures to create potentially safe drugs during discovery and early development relies on a combination of predictive algorithms, screening, formal toxicology studies, and early clinical trials. Early in the process three critical questions emerge that must be answered by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics